Binimetinibi
Binimetinibi
$10,000.00
Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK)1/2, which are components of the RAS/RAF/MEK/ERK pathway.
Author: Michael Ramirez
Publisher: Datamonitor Healthcare
- Description
- Contents
Drug Overview
Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK)1/2, which are components of the RAS/RAF/MEK/ERK pathway. Inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition of the production of various inflammatory cytokines including interleukin-1, -6, and tumor necrosis factor.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 binimetinib : Colorectal cancer (CRC)
18 binimetinib : Melanoma
LIST OF FIGURES
9 Figure 1: Binimetinib for colorectal cancer – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary for binimetinib in colorectal cancer
11 Figure 3: Datamonitor Healthcare’s drug assessment summary for binimetinib in colorectal cancer
13 Figure 4: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
25 Figure 5: Binimetinib for melanoma – SWOT analysis
26 Figure 6: Datamonitor Healthcare’s drug assessment summary of binimetinib for melanoma
27 Figure 7: Datamonitor Healthcare’s drug assessment summary of binimetinib for melanoma
29 Figure 8: Binimetinib sales for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: Binimetinib drug profile
8 Table 2: Binimetinib Phase III data in colorectal cancer
14 Table 3: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
16 Table 4: Patients treated with binimetinib in the US and five major EU markets, by country, 2016–25
19 Table 5: Binimetinib drug profile
21 Table 6: Binimetinib Phase III data in melanoma
24 Table 7: Binimetinib Phase II data in melanoma
30 Table 8: Binimetinib sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
32 Table 9: Binimetinib patient numbers for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the